Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.

AIM We previously reported that glycemic control deteriorated in patients receiving atorvastatin, which is useful for the treatment of hypercholesterolemia in patients with type 2 diabetes. Pitavastatin has a strong lipid-lowering effect, comparable to that of atorvastatin, but it is unknown whether pitavastatin has an adverse influence on glycemic control. The aim of this study was to examine. The effects of three different statins (pravastatin, atorvastatin, and pitavastatin) on blood glucose and HbA(1C) levels in diabetic patients. METHODS We retrospectively compared glycemic control between groups receiving atorvastatin (10 mg/day, group A, n=99), pravastatin (10 mg/day, group Pr, n=85), and pitavastatin (2 mg/day, group Pi, n=95) from the start of treatment until 3 months later. Patients were excluded if the dosage of their antidiabetic drugs was changed, if their drug therapy was altered within 3 months before starting statin therapy, or if events occurred that could affect glycemic control such as hospitalization. RESULTS The subjects available for analysis were 74 patients from group A, 71 patients from group Pr, and 74 patients from group Pi. Arbitrary blood glucose levels increased from 147+/-51 mg/dL (mean+/-SD) to 176+/-69 mg/dL in group A, but only changed minimally from 136+/-31 to 134+/-32 mg/dL in group Pr and from 155+/-53 to 154+/-51 mg/dL in group Pi. HbA(1C) increased from 7.0+/-1.1% to 7.4+/-1.2% in group A, while it was 6.9+/-0.9% versus 6.9+/-1.0% in group Pr, and 7.3+/-1.0% versus 7.2+/-1.0% in group Pi. There was no correlation between Delta LDL-C and Delta HbA(1C) (the change from baseline to 3 months) in any of the groups. CONCLUSION The glycemic parameters only increased significantly in group A, suggesting that pitava-statin and pravastatin did not have an adverse influence on glycemic control in type 2 diabetic patients.

[1]  Peter Lindgren,et al.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .

[2]  M. Nakata,et al.  Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control , 2006, Diabetologia.

[3]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[4]  J. Reckless,et al.  Pitavastatin , 2005, Reactions Weekly.

[5]  M. Laakso,et al.  Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases: Executive Summary , 2007 .

[6]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[7]  James W. Anderson,et al.  Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). , 2003, Diabetes care.

[8]  X. Cheng,et al.  Pitavastatin, a 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitor, Blocks Vascular Smooth Muscle Cell Populated-Collagen Lattice Contraction , 2004, Journal of cardiovascular pharmacology.

[9]  H. Shimano,et al.  Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. , 2006, Journal of atherosclerosis and thrombosis.

[10]  J. Sasaki,et al.  Statins: beneficial or adverse for glucose metabolism. , 2006, Journal of atherosclerosis and thrombosis.

[11]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[12]  K. Shimokado,et al.  MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. , 2004, Life sciences.

[13]  J. Stengård,et al.  Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease , 1994, The Lancet.

[14]  L. Ignarro,et al.  A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. , 2004, Atherosclerosis.

[15]  M. Nakata,et al.  Inhibition by simvastatin, but not pravastatin, of glucose‐induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L‐type Ca2+ channels in rat islet β‐cells , 1999, British journal of pharmacology.

[16]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[17]  J. Sasaki,et al.  Clinical Efficacy of Pitavastatin, a New 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitor, in Patients with Hyperlipidemia , 2002, Arzneimittelforschung.

[18]  S. Pocock,et al.  Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.

[19]  A. Dutour,et al.  Efficacy of Pitavastatin , a New HMG-CoA Reductase Inhibitor , on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes , 2005 .

[20]  I. Kitajima,et al.  Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. , 2005, Life sciences.

[21]  T. Kurata,et al.  Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. , 2004, Atherosclerosis.

[22]  E. Sato,et al.  Enhanced oxidative stress in neutrophils from hyperlipidemic guinea pig. , 2005, Atherosclerosis.

[23]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[24]  T. Yamakawa,et al.  Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. , 2006, Journal of atherosclerosis and thrombosis.

[25]  T. Maejima,et al.  Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. , 2004, Biochemical and biophysical research communications.

[26]  L. Chamberlain.  Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3‐L1 adipocytes , 2001, FEBS letters.

[27]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.